These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 21091098)

  • 61. The cost of being a woman.
    Haas J
    N Engl J Med; 1998 Jun; 338(23):1694-5. PubMed ID: 9614265
    [No Abstract]   [Full Text] [Related]  

  • 62. Broad Hepatitis C Treatment Scenarios Return Substantial Health Gains, But Capacity Is A Concern.
    Van Nuys K; Brookmeyer R; Chou JW; Dreyfus D; Dieterich D; Goldman DP
    Health Aff (Millwood); 2015 Oct; 34(10):1666-74. PubMed ID: 26438742
    [TBL] [Abstract][Full Text] [Related]  

  • 63. When Opportunity Knocks, What Does It Say?
    Phelps CE
    Value Health; 2019 Aug; 22(8):851-853. PubMed ID: 31426924
    [No Abstract]   [Full Text] [Related]  

  • 64. Changing mortality patterns, health services utilization, and health care expenditures.
    Rice DP; Rosenberg HM; Curtin LR; Hodgson TA
    Vital Health Stat 3; 1983 Sep; (23):1-35. PubMed ID: 6417904
    [No Abstract]   [Full Text] [Related]  

  • 65. Economic data and the analysis of health-related issues of the elderly.
    Menefee JA
    Vital Health Stat 4; 1988 Dec; (25):56-71. PubMed ID: 3149072
    [No Abstract]   [Full Text] [Related]  

  • 66. Higher Health Care Costs in Middle-aged US Adults With Hearing Loss.
    Simpson AN; Simpson KN; Dubno JR
    JAMA Otolaryngol Head Neck Surg; 2016 Jun; 142(6):607-9. PubMed ID: 27054903
    [No Abstract]   [Full Text] [Related]  

  • 67. More needs to be spent on hepatitis C treatment, not less.
    Clark PJ; Muranushi C; Hollingworth SA
    Intern Med J; 2018 Mar; 48(3):364-366. PubMed ID: 29512321
    [No Abstract]   [Full Text] [Related]  

  • 68. Characteristics of a hepatitis C patient cohort at a specialized tertiary care facility: Identifying criteria to improve the allocation of public health resources.
    de Matos MLM; Ferrufino RQ; Nastri ACSS; Odongo FCA; Campos AF; Luiz AM; Lisboa-Neto G; Witkin SS; Mendes-Correa MC
    Clinics (Sao Paulo); 2019; 74():e1286. PubMed ID: 31664420
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Monitoring purchaser expenditure patterns.
    Wilson RC; Gilthorpe MS
    IMA J Math Appl Med Biol; 1995; 12(3-4):211-23. PubMed ID: 8919558
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Average price paid for 162 common medical services by state. Ranked by the ratio of state average to the national average.
    Mod Healthc; 2016 May; 46(18):34. PubMed ID: 27366802
    [No Abstract]   [Full Text] [Related]  

  • 71. Hepatitis C.
    Jensen D
    J Insur Med; 1995; 27(2):116-23. PubMed ID: 15323078
    [No Abstract]   [Full Text] [Related]  

  • 72. Spend less on drug enforcement and more on treating hepatitis C, say campaigners.
    Kmietowicz Z
    BMJ; 2013 May; 346():f3428. PubMed ID: 23719747
    [No Abstract]   [Full Text] [Related]  

  • 73. Should obesity be considered a disease?
    Stoner L; Gaffney K; Wadsworth D; Page R
    Perspect Public Health; 2014 Nov; 134(6):314-5. PubMed ID: 25344514
    [No Abstract]   [Full Text] [Related]  

  • 74. Pay now or pay (more) later: tracking the costs of hepatitis C infection.
    Myers RP; Lee SS
    Can J Gastroenterol; 2010 Dec; 24(12):715-6. PubMed ID: 21165378
    [No Abstract]   [Full Text] [Related]  

  • 75. [Health investigation investment and the burden of disease because of hepatitis B and C].
    García-Fulgueiras A; García-Pina R; García-Ortúzar V
    Rev Esp Salud Publica; 2009; 83(4):587-8; author reply 589-91. PubMed ID: 19893886
    [No Abstract]   [Full Text] [Related]  

  • 76. Life is a Ponzi scheme.
    Petsko GA
    Genome Biol; 2009; 10(1):101. PubMed ID: 19226430
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Quality of life of women living with hepatitis C.
    Thein HH; Haber PS; Dore GJ
    J Gastroenterol Hepatol; 2003 Dec; 18(12):1329-31. PubMed ID: 14675259
    [No Abstract]   [Full Text] [Related]  

  • 78. Predicting the impact of adverse events and treatment duration on medical resource utilization-related costs in hepatitis C genotype 1 treatment-naïve patients receiving antiviral therapy.
    Akpo EI; Cerri K; Kleintjens J
    Pharmacoeconomics; 2015 Apr; 33(4):409-22. PubMed ID: 25577042
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Generalizing observational study results: applying propensity score methods to complex surveys.
    Dugoff EH; Schuler M; Stuart EA
    Health Serv Res; 2014 Feb; 49(1):284-303. PubMed ID: 23855598
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Analysis of the Economic-Financial Efficiency of Gout Treatment in Elderly Patients with Comorbidities in the Republic of Moldova.
    Rotaru L; Groppa L; Russu E; Cazac V; Agachi S; Cătălin C; Spinei L; Arnaut O; Sârbu O; Cornea C
    Mediterr J Rheumatol; 2023 Sep; 34(3):327-331. PubMed ID: 37941869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.